Cyclosporine After Heart Attack Leads to Smaller Infarcts
Drug reduces infarct size with no detrimental effect on left ventricle remodeling
FRIDAY, March 19 (HealthDay News) -- Heart attack patients given a single dose of cyclosporine during reperfusion have smaller infarcts, with no adverse effects on left ventricle remodeling, according to a study in the March 23 issue of the Journal of the American College of Cardiology.
Nathan Mewton, M.D., from Université Claude Bernard Lyon in France, and colleagues performed cardiac magnetic resonance imaging (MRI) on 15 patients given a single dose of cyclosporine at the time of percutaneous coronary intervention for ST-segment elevation myocardial infarction; 13 other patients who did not receive cyclosporine also underwent MRI.
At six months, the researchers found that the infarct size was significantly smaller in the cyclosporine group. Left ventricle end-systolic volume was also significantly reduced in the cyclosporine group at both five days and six months. The two groups had similar global left ventricle mass and regional wall thickness of the remote non-infarcted myocardium. There was a significant correlation between infarct size and left ventricular end-diastolic volume, left ventricular end-systolic volume, and left ventricular ejection fraction at six months.
The researchers "describe a rare event: a negative study with potentially enormous impact," write the authors of an accompanying editorial. The study "is an important advance and seems to be the first practical step toward putting the genie of reperfusion injury back in the bottle."